A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
HOPE-3 is a multi-center, randomized, double-blind, placebo-controlled clinical trial
evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants
with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who
meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo
every 3 months for a total of 4 doses during a 12-month period.